- ASSISTANT PROFESSOR Medicine, Nephrology
American Board of Orthopaedic Surgery
MD, New York Medical College
St. Lukes Roosevelt Hospital
St. Lukes Roosevelt Hospital
Fellowship, Sports Medicine
Kaiser Permanente Medical Center
Dr. Barash is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and a full time clinical faculty member of the Mount Sinai Beth Israel (MSBI) Division of Nephrology with a clinical focus on Autosomal Dominant Polycystic Kidney Disease. She is the Director of the MSBI Polycystic Kidney Disease (PKD) Program. The MSBI PKD Program mission is to provide excellent clinical care, conduct clinical research and lead patient education and outreach programs. Dr. Barash has collaborated with the Department of Body Radiology to establish a method for magnetic resonance imaging (MRI) 3D kidney volume measurements, a cutting-edge technique to monitor PKD progression and response to therapy. She is the MSBI Site Principal Investigator for the clinical trial of tolvaptan in chronic kidney disease due to PKD. She has organized a PKD Patient Education Workshop to share with the New York PKD patients the important advances in management of PKD-related cardiovascular health, nutrition, chronic kidney disease, as well as research updates.
New York Rising Stars- Nephrology
Superdoctors.com & NY Times Magazine
Nephrology Faculty of the Year Award
NYU School of Medicine
Dorothea Zucker-Franklin Award for Excellence
NYU School of Medicine
Summa Cum Laude
Dr. Barash’s research centers on Autosomal Dominant Polycystic Kidney Disease (ADPKD), focusing on translational studies and clinical therapeutic trials. Dr. Barash’s advanced research training led to a Master of Science degree in Clinical Research from the Icahn School of Medicine at Mount Sinai. She conducted and published a pilot clinical study of water loading to decrease levels of cAMP (a cyst growth signal) in ADPKD. She currently serves as the MSBI Site Principal Investigator of the Phase 3b trial of tolvaptan efficacy for ADPKD. This is a global trial that is addressing the efficacy of tolvaptan in slowing disease progression in ADPKD patients who have reduced kidney function.
Cohen BA, Barash I, Kim DC, Sanger MD, Babb JS, Chandarana H. Intraobserver and interobserver variability of renal volume measurements in polycystic kidney disease using a semiautomated MR segmentation algorithm. AJR. American journal of roentgenology 2012 Aug; 199(2).
Kwa M, Baumgartner R, Shavit L, Barash I, Michael J, Puzanov I, Kopolovic J, Rosengarten O, Blank S, Curtin JP, Gabizon A, Muggia F. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?. The oncologist 2012; 17(12).
Barash I, Ponda MP, Goldfarb DS, Skolnik EY. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clinical journal of the American Society of Nephrology : CJASN 2010 Apr; 5(4).
Ponda MP, Barash I, Feig JE, Fisher EA, Skolnik EY. Moderate kidney disease inhibits atherosclerosis regression. Atherosclerosis 2010 May; 210(1).
Ponda MP, Barash I. Lipid metabolism in dialysis patients-the story gets more complicated. Seminars in dialysis; 21(5).
Wyatt CM, Winston JA, Malvestutto CD, Fishbein DA, Barash I, Cohen AJ, Klotman ME, Klotman PE. Chronic kidney disease in HIV infection: an urban epidemic. AIDS (London, England) 2007 Oct; 21(15).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Barash did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
10 Union Square East, Suite 2F
New York, NY 10003